The Conversation (0)
LivaNova (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2018. As quoted in the press release: For the third quarter of 2018, worldwide sales from continuing operations were $272.1 million, an increase of 8.3 percent on a reported basis and an increase of 10.3 percent on a …
LivaNova (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2018.
As quoted in the press release:
For the third quarter of 2018, worldwide sales from continuing operations were $272.1 million, an increase of 8.3 percent on a reported basis and an increase of 10.3 percent on a constant currency basis, as compared to the same quarter of the previous year. On the basis of U.S. Generally Accepted Accounting Principles (GAAP), third quarter 2018 diluted loss per share from continuing operations was $0.13. Third quarter 2018 adjusted diluted earnings per share from continuing operations were $0.78. Adjusted results include a non-recurring return reserve that reduced third quarter sales by approximately $3.4 million and adjusted diluted earnings per share by approximately $0.04.
“The third quarter results reflect our continued momentum in accelerating our sales growth while making significant investments to deliver on our long-term strategy. Results for third quarter 2018 were strong across all regions,” said Damien McDonald, Chief Executive Officer of LivaNova.